REDMILE GROUP LLC
Q2 2026 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001425738
· CRD 143606
· SEC-registered investment adviser
$1.5B Reported Value Total
REDMILE GROUP reports 26 total accounts under management (AUM). There are 26 discretionary accounts valued at $4,701,099,967, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
27 funds
· $7.7B gross asset value
Hedge Fund: $5.4B · Venture Capital Fund: $1.2B · Private Equity Fund: $1.1B
Source: Form ADV filed 2026-08-28
Reported value
$1.5B
Quarter over quarter
+21.5%
Holdings
39
Top-10 concentration
73.5%
Key People
Form ADV owners & control persons
Jeremy Charles Green
MANAGING MEMBER
Michael Stewart Lee
MANAGING DIRECTOR
Bryan Ranney Crapo
CHIEF OPERATING OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $1.5B |
| Positions | 39 |
| Change in reported value | -1.4% |
| New positions | 4 |
| Exited positions | 0 |
| Position turnover | 10.3% |
| Top-10 concentration | 73.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
39 | $1.5B |
|
Q1 2026 13F
Filed May 15, 2026
|
35 | $1.5B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
34 | $1.4B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
40 | $1.0B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
48 | $939.6M |
|
Q1 2025 13F
Filed May 15, 2025
|
56 | $1.1B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
62 | $1.4B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
63 | $1.7B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
63 | $1.7B |
|
Q1 2024 13F
Filed May 15, 2024
|
77 | $2.7B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
70 | $2.8B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
68 | $2.1B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
72 | $2.6B |
|
Q1 2023 13F
Filed May 15, 2023
|
76 | $2.3B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
69 | $2.4B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
70 | $2.6B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
71 | $2.6B |
|
Q1 2022 13F
Filed May 16, 2022
|
70 | $3.2B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
71 | $4.4B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
75 | $5.7B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | SRRK SCHOLAR ROCK HLDG CORP | $237.1M | 15.92% |
| 2 | KRYS KRYSTAL BIOTECH INC | $234.9M | 15.77% |
| 3 | STOK STOKE THERAPEUTICS INC | $129.1M | 8.67% |
| 4 | IMNM IMMUNOME INC | $104.1M | 6.99% |
| 5 | NRIX NURIX THERAPEUTICS INC | $98.8M | 6.64% |
| 6 | ABSI ABSCI CORPORATION | $78.1M | 5.24% |
| 7 | ANNX ANNEXON INC | $67.8M | 4.55% |
| 8 | RGNX REGENXBIO INC | $52.3M | 3.51% |
| 9 | STTK SHATTUCK LABS INC | $47.8M | 3.21% |
| 10 | NGNE NEUROGENE INC | $44.4M | 2.98% |
| 11 | BEAM BEAM THERAPEUTICS INC | $40.0M | 2.68% |
| 12 | AGMB AGOMAB THERAPEUTICS NV | $35.5M | 2.38% |
| 13 | FATE FATE THERAPEUTICS INC | $34.8M | 2.33% |
| 14 | IDYA IDEAYA BIOSCIENCES INC | $23.9M | 1.6% |
| 15 | SLN SILENCE THERAPEUTICS PLC | $23.8M | 1.6% |
| 16 | COGT COGENT BIOSCIENCES INC | $19.5M | 1.31% |
| 17 | SLDB SOLID BIOSCIENCES INC | $19.5M | 1.31% |
| 18 | NUVB NUVATION BIO INC | $17.2M | 1.16% |
| 19 | CLDX CELLDEX THERAPEUTICS INC NEW | $16.1M | 1.08% |
| 20 | ELYM CLIMB BIO INC | $16.0M | 1.07% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.